ements
contained herein are made only as of the date of this press release, and
the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
For the For the
Three Months Ended Three Months Ended
December 31, December 31,
2007 2006
Revenue $6,250 $181,250
Operating Expenses:
General and administrative 585,851 1,103,594
Research and development 392,254 239,395
Total Operating Expenses 978,105 1,342,989
Loss From Operations (971,855) (1,161,739)
Sale of state income tax loss, net -- --
Other noncash income -- --
Interest income, net 25,227 26,102
Amortization of debt discount
and financing costs (283,207) --
Interest expense on
convertible notes (64,836) --
Net Loss $(1,294,671) $(1,135,637)
Basic and Diluted
Net Loss Per Common Share $(0.07) $(0.07)
Basic and Diluted
Weighted Average Number
of Common Shares Outstanding 17,474,870 17,257,791
From
'/>"/>
SOURCE Senesco Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing2.
Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies3.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering4.
Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction5.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results6.
BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery7.
Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators8.
China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day9.
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth10.
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership11.
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel